PriceSensitive

PainChek (ASX:PCK) to expand into Japan via JETRO Business Connect program

ASX News, Health Care
ASX:PCK      MCAP $49.07M
26 September 2022 13:03 (AEST)

This browser does not support the video element.

PainChek (PCK) is expanding its activities to Japan after being accepted into the JETRO Business Connect program for 2022.

JETRO is Japan’s core governmental organisation for promoting inward foreign business. It provides support for foreign and foreign-affiliated companies planning to invest in Japan to connect them with local communities and towns throughout the country.

As part of its program, PainChek will receive support services such as a broad range of Japan market data, online business matching events connecting it with local partners, as well as guidance in relation to gaining regulatory clearances in Japan.

The company said it was accepted into the JETRO program after face-to-face meetings in London and achieving the set criteria under JETRO’s screening process.

The pain assessment technology company said with 29.1 per cent of Japan’s population being 65 years and over, there was an “excellent opportunity” for PainChek within the Japanese market.

“Both parties are excited by the potential for collaboration with organisations in Japan and the positive outcomes it could lead to,” PainChek CEO Philip Daffas said.

“This new initiative, combined with our recent contact with FDA, means PainChek can now plan effectively for market entry into the US and Japan — two of the world’s largest medical device and aged care markets.”

PainChek will now virtually meet with other companies, research groups and government officials across Japan to assist in business development opportunities in the country.

Company shares were up 3.23 per cent to 3.2 cents at 1:01 pm AEST.

Related News